Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Aug 7;107(4):588-91.
doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26.

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

U Wagner  1 , C Marth, R Largillier, J Kaern, C Brown, M Heywood, T Bonaventura, I Vergote, M C Piccirillo, R Fossati, V Gebski, E P Lauraine
Affiliations
Clinical Trial

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

U Wagner et al. Br J Cancer. .

Abstract

Background: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature.

Methods: Women with ROC relapsing > 6 months after first- or second-line therapy were randomised to CD or CP for six cycles in this international, open-label, non-inferiority trial. The primary endpoint was progression-free survival. The OS analysis is presented here.

Results: A total of 976 patients were randomised (467 to CD and 509 to CP). With a median follow-up of 49 months, no statistically significant difference was observed between arms in OS (hazard ratio = 0.99 (95% confidence interval 0.85, 1.16); log-rank P = 0.94). Median survival times were 30.7 months (CD) and 33.0 months (CP). No statistically significant difference in OS was observed between arms in predetermined subgroups according to age, body mass index, treatment-free interval, measurable disease, number of lines of prior chemotherapy, or performance status. Post-study cross-over was imbalanced between arms, with a greater proportion of patients randomised to CP receiving post-study PLD (68%) than patients randomised to CD receiving post-study paclitaxel (43%; P < 0.001).

Conclusion: Carboplatin-PLD led to delayed progression and similar OS compared with carboplatin-paclitaxel in platinum-sensitive ROC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival in patients receiving carboplatin-paclitaxel or carboplatin-PLD for platinum-sensitive recurrent ovarian cancer. Abbreviation: PLD, pegylated liposomal doxorubicin.
See this image and copyright information in PMC

References

    1. Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis PE, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM (2010) A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 8: 3. - PMC - PubMed
    1. Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18: 263–268 - PubMed
    1. Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S (2011) Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 23: 1185–1189 - PubMed
    1. González-Martín AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E, Herrero A, Pardo B, Adrover E, Rifá J, Godes MJ, Moyano A, Cervantes A (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. Ann Oncol 16: 749–755 - PubMed
    1. Gordon A, Fleagle J, Guthrie D, Parkin D, Gore M, Lacave A (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312–3322 - PubMed

Publication types

MeSH terms